New hope for kidney cancer: drug combo shows promise in early trial
NCT ID NCT07159191
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs—envafolimab (an immunotherapy) and axitinib (a targeted therapy)—in 30 people with advanced kidney cancer that has not been treated before. The goal is to see if the combo can shrink tumors and control the disease safely. Participants receive treatment for up to 2 years, with regular scans to check progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA (ARCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.